Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

Restricted access

Background: Angiosarcoma is a malignant neoplastic disease originating from or differentiating toward vascular endothelium, for which systemic pharmacologic treatment has limited durability. The molecular oncogenesis of angiosarcoma is often linked to inappropriate activations of vascular endothelial growth factor receptor (VEGFR) family members, which presents an opportunity for the use of therapy that selectively targets the machinery of vascular signaling. Methods: Hybridization capture of 3,320 exons of 182 cancer-related genes and the introns of 14 genes frequently rearranged in cancer was applied to more than 50 ng of DNA extracted from a formalin-fixed, paraffin-embedded biopsy of recurrent angiosarcoma and was sequenced to high, uniform coverage of 939x. Results: The angiosarcoma harbored amplifications of VEGFR2 (KDR) of 8 copies and VEGFR3 (FLT4) of 16 copies. The patient was initially treated with sorafenib, an inhibitor of VEGFR2, and developed progressive disease. The patient then received pazopanib, an inhibitor of VEGFR2 and VEGFR3 and experienced a potent antitumor response resulting in clinically stable disease for 6 months. Conclusions: This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.

Current affiliation: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Correspondence: Vinod Ravi, MD, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: vravi@mdanderson.org
  • 1.

    FataFO'ReillyEIlsonD. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer1999;86:20342037.

  • 2.

    FuryMGAntonescuCRVan ZeeKJ. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J2005;11:241247.

    • Search Google Scholar
    • Export Citation
  • 3.

    ParkMSRaviVAraujoDM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol2010;22:351355.

    • Search Google Scholar
    • Export Citation
  • 4.

    AgulnikMYarberJLOkunoSH. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol2013;24:257263.

    • Search Google Scholar
    • Export Citation
  • 5.

    MakiRGD'AdamoDRKeohanML. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol2009;27:31333140.

    • Search Google Scholar
    • Export Citation
  • 6.

    FramptonGMFichtenholtzAOttoGA. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol2013;31:10231031.

    • Search Google Scholar
    • Export Citation
  • 7.

    GuoTAgaramNPWongGC. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res2007;13:48744881.

    • Search Google Scholar
    • Export Citation
  • 8.

    van der GraafWTBlayJYChawlaSP. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2012;379:18791886.

    • Search Google Scholar
    • Export Citation
  • 9.

    AntonescuCRYoshidaAGuoT. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res2009;69:71757179.

    • Search Google Scholar
    • Export Citation
  • 10.

    GuoTZhangLChangNE. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer2011;50:2533.

    • Search Google Scholar
    • Export Citation
  • 11.

    von MehrenMRandallRLBenjaminRS. NCCN Clinical Practice Guidelines in Oncology; Soft Tissue Sarcoma. Version 2.2016. Accessed April 4 2016. To view the most recent version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 12.

    RaviVPatelS. Vascular sarcomas. Curr Oncol Rep2013;15:347355.

  • 13.

    JussilaLAlitaloK. Vascular growth factors and lymphangiogenesis. Physiol Rev2002;82:673700.

  • 14.

    YancopoulosGDDavisSGaleNW. Vascular-specific growth factors and blood vessel formation. Nature2000;407:242248.

  • 15.

    European Medicines Agency. CHMP assessment report: Votrient. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001141/WC500094275.pdfAccessed April 3 2016.

    • Search Google Scholar
    • Export Citation
  • 16.

    KitagawaDYokotaKGoudaM. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells2013;18:110122.

  • 17.

    OngPGreulichSSchummJ. Favorable course of pericardial angiosarcoma under Paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging. Circulation2012;126:e279281.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 620 620 71
PDF Downloads 154 154 26
EPUB Downloads 0 0 0